Scott Matson
@scott_matson
Followers
475
Following
2K
Media
56
Statuses
718
Pulm/ccm doctor interested in ILD and pragmatic trial design
Joined July 2011
RT @ATSBlueEditor: Decoding Molecular Heterogeneity in Idiopathic Pulmonary Fibrosis.@atscommunity . š https://t.cā¦.
0
6
0
Tough week on NIH funding front, R21 that scored 8% was ānot fundedā on Monday and second grant was ānot discussedā this weekend. Iām undeterred, āthe obstacle becomes the way,ā but also
0
0
7
Small cohort but promising findings as an approach to cluster and classify groups of idiopathic and autoimmune ILD patients across the spectrum of inflammation and fibrosis @KaminskiMed @KerriBerriKerri @DrPujaMehta1 @EBRheum @aravindamenon @drdayjee @IPFdoc.
2
0
6
Excited to share the first paper from the Matson lab! Here we used label free quant proteomics of the lung microenviron (BALF) to ID molecular clusters across IPF and IPAF. Clusters had unique survival trajectories and outperformed GAP index.
3
2
24
RT @CUHemeOnc: Big congratulations to our former HemeOnc fellow and current Assistant Professor, Medicine-Medical Oncology, Dr. Tejas Patilā¦.
0
4
0
RT @SenSanders: Three months after launching our investigation into the outrageously high cost of inhalers in this country, three major manā¦.
0
2K
0
RT @EBRheum: Thanks for participating! Really enjoyed the conversation. Great thoughts on risk/benefits of screening, ideal mgmt for pts w/ā¦.
0
2
0
RT @jeffsparks: Our editorial about the bi-directional association of RA and COPD. Fun to write this with Dr Julia Ford (previous @BrighamWā¦.
0
4
0
RT @KDemoruelle: See our new collaborative study that found elevations of peripheral Tph cells in pre-RA #rheumatoidarthritis @CURheumatoloā¦.
0
2
0
RT @ErikVanZwet: Don't like p-values? We're presenting a completely new interpretation in the context of clinical trials. With Andrew Gelmaā¦.
0
376
0
Even when wearing a tux, @FibroticJayhawk still teaching us all about pulmonary fibrosis. KC Pulmonary fibrosis foundation fundraiser
0
0
9
0
0
2
Small, but if the effect size is large, small can still be important. One of the first studies that shows large benefits for quality of life and patient reported outcomes for patients with IPF. Crossover, randomized trial with well done objective and subjective cough measures.
āIn this short-term crossover trial, [nalbuphine extended-release tablets] reduced cough in individuals with [idiopathic pulmonary fibrosis]. Larger and longer trials are needed to assess the impact on cough versus drug adverse effects.ā. #RCT #PulmCC #RespEd @TobyMMaher.
2
1
12
No better pulmonary physiology teacher than Rick Albert, always kind of grumpy, but always insightful. When I was an intern in 2013 he was chair at DH, he came to every single noon report that year, he was always so concerned about the respiratory rate! Learned a ton.
Dr Albert giving a very special lecture āMusings from 50 Years as a Pulmonary and Critical Care Docā. Not the ski pole as a pointer šš
0
0
3
Mark your calendar, what a fantastic conference. Greece!.
0
0
5
Had this experience 2x (same person) during junior faculty mentoring meetings where I presented my āplanā to senior faculty/mentors. Didnāt stop there either as he proceeded to email blast everyone in our institution re: his concerns. never met w/ me or included me in the emails.
0
0
2
KU growing and growing, this will be a fantastic addition to campus.
BREAKING: @KUcancercenter @KUHospital @KUMedCenter unveil new building that will combine research and clinical care. $100 million gift from Sunderland Foundation jumpstarts fundraising. #BreakingNews
0
0
8
If anyone seeing ILD pts wants to join a prospective patient reported outcome project send me a DM or reply here! Weāve got IRB language I can supply and it takes less than 1 minute in the room with patient and 8 minutes for patient to fill out a survey after #ILDtwitter
2
10
19